-
ADA President, Medicine & Science: Closing the circle from progress to promise is our unfinished journey
While the diabetes community has yet to reach the ultimate goal of improving health outcomes for every person living with diabetes, great strides have been made. Rita Rastogi Kalyani, MD, MHS, the ADA’s President, Medicine & Science, said the path forward needs to include professional education and advocacy.
-
Banting Medalist explains how beta cells hold the key to type 2 diabetes
Steven E. Kahn, MB, ChB, accepted the Banting Medal for Scientific Achievement on Sunday at the Scientific Sessions. His lab identified a hyperbolic relationship between beta cell response and insulin sensitivity in the early 1990s. In his award lecture, he discussed how this dynamic fits into pathogenesis and progression of type 2 diabetes.
-
Speakers will dispel myths about muscle and energy expenditure
Lara Dugas, PhD, MPH, and other panelists will examine the impact of common misconceptions and summarize new insights about the dynamics of muscle mass, energy expenditure, and individual metabolism.
-
Panel to explain why smarter is better in pediatric diabetes
Pediatric endocrinologist and physician-scientist Mustafa Tosur, MD, FAAP, will open a symposium on trending topics and smart solutions for diagnosing and managing diabetes in children, adolescents, and young adults.
-
Experts to present new approaches to lower triglycerides, pancreatitis risk
Panelists, including Savitha Subramanian, MD, will detail the latest therapies for severe hypertriglyceridemia, the genetics of hypertriglyceridemia, and the dynamics of hypertriglyceridemia-induced acute pancreatitis
-
PATHWEIGH demonstrates significant weight loss for novel primary care model
Speakers shared evidence of population-wide weight loss and improved use of weight-related treatment. Mark Gritz, PhD, said the goal was affordable care delivery that could be implemented broadly.
-
2025 Outstanding Educator in Diabetes Award honoree focuses on nutrition
Alison Evert, MS, RDN, CDCES, discussed three key components of diabetes nutrition therapy in her award lecture: research, recommendations, and real-world experiences.
-
Symposium features promise of non-peptide GLP-1 RAs and first report of phase 3 ACHIEVE-1
Julio Rosenstock, MD, shared data from ACHIEVE-1 that show orforglipron led to reductions in A1C and meaningful weight loss as monotherapy in drug-naïve type 2 diabetes with inadequate glycemic management.
Presenter Profiles
